银屑病治疗市场：按治疗方法、通路和地区划分

据估计，2026 年银屑病治疗市场价值为 342 亿美元，预计到 2033 年将达到 715 亿美元，2026 年至 2033 年的复合年增长率为 11.1%。

随着医学研究人员从一般免疫抑制转向高度标靶化的免疫通路，干癣治疗市场正在发生显着变化，扩大了长期缓解的可能性。白细胞介素(IL) 抑制剂、TYK2 抑制剂的策略性进展以及生物相似药的日益普及，在影响这些市场动态发挥关键作用。干癣管理方案已成为包括皮肤科、风湿科和基层医疗在内的多个临床学科的重要医疗保健工具。

生物标记数据与人工智慧驱动的治疗方案相结合，提高了疾病管理的精确度和一致性。非类固醇泡沫剂和窄频UVB照光治疗等创新给药系统，正在提升患者依从性并改善安全性。这种转变为提供高效、疗效稳定且安全性良好的生物製药和口服小分子药物的医疗机构创造了竞争优势。这些突破使临床医生能够提供个人化治疗，旨在全面改善全球数百万患者的皮肤状况并提高其生活品质。

市场动态

银屑病治疗市场正经历显着增长，主要驱动力来自皮肤病学和免疫学领域日益增长的需求。在全球对长期改善皮肤状况的需求不断增长的背景下，生物製药因其卓越的靶向性、安全性以及对中重度病例的高效性，正逐渐成为首选治疗方案。製药公司越来越多地采用白细胞介素类药物来满足严格的临床标准并改善患者的生活质量，尤其是在全球医疗体係日益收紧慢性病管理和白细胞介素控制相关法规的情况下。这些变化使得患者能够获得针对疾病系统性根本原因而非仅针对錶面症状的有效治疗。

IL-17 和 IL-23 抑制剂在临床应用中的日益普及，显着推动了精准医疗的需求，并对市场产生了积极影响。现代生物製药的天然特性，例如快速清除斑块、持久缓解、患者依从性高以及易于自行注射等，使其成为皮肤健康领域多种应用的理想选择。利用先进的分子定位标记，医生可以更清楚地了解患者的免疫反应，并有效纠正导致皮肤出现红肿搔痒斑块的过度活跃路径。

此外，由于零售药局中口服小分子药物和生物相似药的使用日益增多，消费者对价格适中且无需注射的治疗方案的需求不断增长，推动了市场的发展。在门诊，居家治疗的普及和便捷的每日给药方式的兴起，也带动了对这些药物的需求。专科药房服务的成长是银屑病治疗市场成长的主要驱动力，因为它提高了患者获得改变生活的药物的可及性。

本次调查的主要特点

• 本报告对银屑病治疗市场进行了详细分析，以 2025 年为基准年，给出了预测期（2026-2033 年）的市场规模（十亿美元）和復合年增长率（%）。
• 它还重点介绍了各个细分市场的潜在商机，并说明了该市场具有吸引力的投资提案矩阵。
• 该研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或核准、市场趋势、区域展望以及主要参与者采取的竞争策略的重要见解。
• 该研究根据以下参数对银屑病治疗市场的主要企业进行了分析：公司概况、产品系列、主要亮点、财务表现和策略。
• 本报告的研究结果将有助于负责人和经营团队就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 这份银屑病治疗市场报告的目标受众是该行业的各种相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
• 相关人员可以透过各种用于分析银屑病治疗市场的策略矩阵轻鬆做出决策。

目录

第一章 研究目标与前提条件

• 调查目的
• 先决条件
• 简称

第二章 市场范围

• 报告概述
  • 市场定义和范围
• 执行摘要

第三章 市场动态、监管与趋势分析

• 市场动态
• 影响分析
• 主要亮点
• 法规环境
• 产品上市及核准情况
• PEST分析
• 波特分析
• 市场机会
• 法规环境
• 重大进展
• 产业趋势

4. 2020-2033年全球干癣治疗市场（依治疗方法）

• 局部治疗
• 全身护理
• 生物製药
• 照光治疗

5. 2020-2033年全球干癣治疗市场依通路

• 医院药房
• 零售药房
• 网路药房
• 专科诊所

6. 2020-2033年全球干癣治疗市场（按地区划分）

• 北美洲
  • 我们
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲国家
• 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 亚太其他地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东国家
• 非洲
  • 南非
  • 北非
  • 中非

第七章 竞争情势

• Glenmark Pharmaceuticals Limited
• Sun Pharmaceuticals Industries Ltd.
• Cipla Ltd.
• Johnson &Johnson
• Rowan Bioceuticals Private Limited
• Stiefel Laboratories Inc.（GlaxoSmithKline plc）
• Win Medicare Pvt. Ltd
• Novartis AG

第八章 分析师建议

• 机会
• 分析师观点
• Coherent Opportunity Map

第九章 参考文献与调查方法

• 参考
• 调查方法
• 关于本公司

Psoriasis Treatment Market is estimated to be valued at USD 34.2 Bn in 2026 and is expected to reach USD 71.5 Bn by 2033, growing at a compound annual growth rate (CAGR) of 11.1% from 2026 to 2033.

The Psoriasis Treatment Market evolves significantly as medical researchers transition from general immunosuppression to highly targeted immunological pathways, broadening the possibilities for long-term remission. Strategic advancements in interleukin (IL) inhibitors, TYK2 inhibitors, and the growing availability of biosimilars play a critical role in influencing these market dynamics. Psoriasis management solutions serve as essential healthcare tools across various clinical segments, including dermatology, rheumatology, and primary care.

The integration of biomarker data and AI powered treatment planning has enhanced the precision and consistency of disease management. Innovative delivery systems such as nonsteroidal foams and narrowband UVB phototherapy have led to higher patient adherence and improved safety standards. This shift creates a competitive advantage for providers who supply high-efficacy biologics and oral small molecules with consistent performance and favorable safety profiles. These breakthroughs allow clinicians to offer personalized treatments that aim for complete skin clearance and improved quality of life for millions of patients worldwide.

Market Dynamics

The Psoriasis Treatment Market is witnessing significant momentum largely driven by escalating demand from the dermatology and immunology sectors. With the global push toward long-term skin clearance, biologic therapies are increasingly preferred for their excellent targeted action, safety profiles, and high efficacy in moderate to severe cases. Pharmaceutical companies are adopting interleukins more proactively to meet strict clinical standards and improve patient quality of life, especially as healthcare systems worldwide tighten rules on chronic disease management and inflammation control. These shifts ensure the patients receive effective care that addresses the systemic roots of the condition rather than just surface symptoms.

The increasing use of IL-17 and IL-23 inhibitors in clinical settings is significantly propelling the demand for precision medicine, thus positively influencing the market. The natural features of modern biologic tools, such as rapid plaque clearing, long-lasting remission, high patient adherence, and easy self-injection, make them an ideal choice for multiple uses in the skin health area. By using better molecular mapping markers, doctors are allowed to keep a clear view of the patient's immune response while effectively fixing the overactive pathways that cause red itchy patches.

Furthermore, the rising use of oral small molecules and biosimilars in the retail pharmacy sector is significantly influencing the growth path of the market due to the need for affordable care and injection-free options. In outpatient clinics the demand for these drugs comes from the ongoing move toward home-based treatment and convenient daily dosing. The growth of specialty pharmacy services has become a major driving force behind the growth of the psoriasis treatment market, as they offer better access to life-changing drugs.

Key Features of the Study

• This report provides in-depth analysis of the Psoriasis Treatment Market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Psoriasis Treatment Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Glenmark Pharmaceuticals Limited, Sun Pharmaceuticals Industries Ltd., Cipla Ltd., Johnson & Johnson, Rowan Bioceuticals Private Limited, Stiefel Laboratories Inc. (GlaxoSmithKline plc), Win Medicare Pvt. Ltd., and Novartis AG
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Psoriasis Treatment Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Psoriasis Treatment Market

Market Segmentation

• Therapy Type Insights (Revenue, USD Bn, 2026 - 2033)
  • Topical Treatments
  • Systemic Treatments
  • Biologics
  • Phototherapy
• Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Clinics
• Regional Insights (Revenue, USD Bn, 2026 - 2033)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • U.K.
  • Germany
  • Italy
  • France
  • Russia
  • Spain
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • North Africa
  • Central Africa
  • South Africa
• Key Players Insights
  • Glenmark Pharmaceuticals Limited
  • Sun Pharmaceuticals Industries Ltd.
  • Cipla Ltd.
  • Johnson & Johnson
  • Rowan Bioceuticals Private Limited
  • Stiefel Laboratories Inc. (GlaxoSmithKline plc)
  • Win Medicare Pvt. Ltd
  • Novartis AG

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Psoriasis Treatment Market, By Therapy Type
  • Global Psoriasis Treatment Market, By Distribution Channel
  • Global Psoriasis Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Market Opportunities
• Regulatory Scenario
• Key Developments
• Industry Trend

4. Global Psoriasis Treatment Market, By Therapy Type, 2020-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Topical Treatments
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Systemic Treatments
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Biologics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Phototherapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)

5. Global Psoriasis Treatment Market, By Distribution Channel, 2020-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)

6. Global Psoriasis Treatment Market, By Region, 2020 - 2033, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

7. Competitive Landscape

• Glenmark Pharmaceuticals Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sun Pharmaceuticals Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Cipla Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Rowan Bioceuticals Private Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Stiefel Laboratories Inc. (GlaxoSmithKline plc)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Win Medicare Pvt. Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

8. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

9. References and Research Methodology

• References
• Research Methodology
• About us